Follow
David Nicol
David Nicol
Royal Marsden Hospital/Institute of Cancer Research/University of Queensland
Verified email at rmh.nhs.uk
Title
Cited by
Cited by
Year
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
M Gerlinger, S Horswell, J Larkin, AJ Rowan, MP Salm, I Varela, R Fisher, ...
Nature genetics 46 (3), 225-233, 2014
13372014
Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal
S Turajlic, H Xu, K Litchfield, A Rowan, T Chambers, JI Lopez, D Nicol, ...
Cell 173 (3), 581-594. e12, 2018
6922018
Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic
A Sud, ME Jones, J Broggio, C Loveday, B Torr, A Garrett, DL Nicol, ...
Annals of Oncology 31 (8), 1065-1074, 2020
5612020
Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal
S Turajlic, H Xu, K Litchfield, A Rowan, S Horswell, T Chambers, ...
Cell 173 (3), 595-610. e11, 2018
5322018
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies
FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ...
Cancer cell 33 (4), 649-663. e4, 2018
5212018
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
A Sud, B Torr, ME Jones, J Broggio, S Scott, C Loveday, A Garrett, ...
The Lancet Oncology 21 (8), 1035-1044, 2020
4662020
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
CS Cooper, R Eeles, DC Wedge, P Van Loo, G Gundem, LB Alexandrov, ...
Nature genetics 47 (4), 367-372, 2015
4612015
Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal
TJ Mitchell, S Turajlic, A Rowan, D Nicol, JHR Farmery, T O’Brien, ...
Cell 173 (3), 611-623. e17, 2018
4502018
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors
FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ...
Immunity 46 (4), 577-586, 2017
3992017
Non‐melanoma skin cancer risk in the Queensland renal transplant population
HM Ramsay, AA Fryer, CM Hawley, AG Smith, DL Nicol, PN Harden
British Journal of Dermatology 147 (5), 950-956, 2002
3332002
The effect of obesity on renal transplant outcomes
DW Johnson, NM Isbel, AM Brown, TD Kay, K Franzen, CM Hawley, ...
Transplantation 74 (5), 675-681, 2002
2842002
Repeat urethrotomy and dilation for the treatment of urethral stricture are neither clinically effective nor cost-effective
TJ Greenwell, C Castle, DE Andrich, JT MacDonald, DL Nicol, AR Mundy
The Journal of urology 172 (1), 275-277, 2004
2762004
Altered cognitive function in men treated for prostate cancer with luteinizing hormone‐releasing hormone analogues and cyproterone acetate: a randomized controlled trial
HJ Green, KI Pakenham, BC Headley, J Yaxley, DL Nicol, PN Mactaggart, ...
BJU international 90 (4), 427-432, 2002
2672002
Mutational signatures of ionizing radiation in second malignancies
S Behjati, G Gundem, DC Wedge, ND Roberts, PS Tarpey, SL Cooke, ...
Nature communications 7 (1), 1-8, 2016
2522016
Molecular subclassification of kidney tumors and the discovery of new diagnostic markers
M Takahashi, XJ Yang, J Sugimura, J Backdahl, M Tretiakova, CN Qian, ...
Oncogene 22 (43), 6810-6818, 2003
2402003
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
DC Wedge, G Gundem, T Mitchell, DJ Woodcock, I Martincorena, M Ghori, ...
Nature genetics 50 (5), 682-692, 2018
2212018
Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display
FK Rae, SA Stephenson, DL Nicol, JA Clements
International Journal of Cancer 88 (5), 726-732, 2000
2082000
Vascular endothelial growth factor expression is increased in renal cell carcinoma
D Nicol, SI Hii, M Walsh, B Teh, L Thompson, C Kennett, D Gotley
The Journal of urology 157 (4), 1482-1486, 1997
1981997
Bone and prostate cancer cell interactions in metastatic prostate cancer
I Vela, L Gregory, EM Gardiner, JA Clements, DL Nicol
BJU international 99 (4), 735-742, 2007
1952007
Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer …
TL Veveris-Lowe, MG Lawrence, RL Collard, L Bui, AC Herington, ...
Endocrine-related cancer 12 (3), 631-643, 2005
1912005
The system can't perform the operation now. Try again later.
Articles 1–20